UBS AM’s Aerie Pharmaceuticals AERI Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2022
Q4 | – | Sell |
-53,554
| Closed | -$810K | – | 2802 |
|
|
2022
Q3 | $810K | Buy |
53,554
+2,310
| +5% | +$26.9K | ﹤0.01% | 2094 |
|
|
2022
Q2 | $384K | Sell |
51,244
-3,549
| -6% | -$25K | ﹤0.01% | 2391 |
|
|
2022
Q1 | $499K | Hold |
54,793
| – | – | ﹤0.01% | 2463 |
|
|
2021
Q4 | $385K | Hold |
54,793
| – | – | ﹤0.01% | 2625 |
|
|
2021
Q3 | $625K | Buy |
54,793
+67
| +0.1% | +$979 | ﹤0.01% | 2408 |
|
|
2021
Q2 | $876K | Buy |
54,726
+12,650
| +30% | +$217K | ﹤0.01% | 2275 |
|
|
2021
Q1 | $752K | Hold |
42,076
| – | – | ﹤0.01% | 2216 |
|
|
2020
Q4 | $568K | Hold |
42,076
| – | – | ﹤0.01% | 2255 |
|
|
2020
Q3 | $495K | Sell |
42,076
-1,168
| -3% | -$14.2K | ﹤0.01% | 2150 |
|
|
2020
Q2 | $638K | Buy |
43,244
+1,522
| +4% | +$22.5K | ﹤0.01% | 2013 |
|
|
2020
Q1 | $563K | Buy |
41,722
+3,586
| +9% | +$68K | ﹤0.01% | 1932 |
|
|
2019
Q4 | $922K | Buy |
38,136
+7,575
| +25% | +$157K | ﹤0.01% | 1954 |
|
|
2019
Q3 | $587K | Buy |
30,561
+3,699
| +14% | +$84.7K | ﹤0.01% | 2204 |
|
|
2019
Q2 | $794K | Sell |
26,862
-4,282
| -14% | -$165K | ﹤0.01% | 2004 |
|
|
2019
Q1 | $1.48M | Sell |
31,144
-72,404
| -70% | -$3.19M | ﹤0.01% | 1663 |
|
|
2018
Q4 | $3.74M | Sell |
103,548
-1,612
| -2% | -$75.6K | ﹤0.01% | 1191 |
|
|
2018
Q3 | $6.47M | Buy |
105,160
+5,536
| +6% | +$356K | ﹤0.01% | 1055 |
|
|
2018
Q2 | $6.73M | Sell |
99,624
-9,818
| -9% | -$549K | 0.01% | 1055 |
|
|
2018
Q1 | $5.94M | Sell |
109,442
-5,371
| -5% | -$300K | ﹤0.01% | 1092 |
|
|
2017
Q4 | $6.86M | Buy |
114,813
+74,130
| +182% | +$4.5M | 0.01% | 1011 |
|
|
2017
Q3 | $1.98M | Buy |
40,683
+23,522
| +137% | +$1.28M | ﹤0.01% | 1412 |
|
|
2017
Q2 | $902K | Buy |
17,161
+4,731
| +38% | +$220K | ﹤0.01% | 1702 |
|
|
2017
Q1 | $564K | Buy |
12,430
+6,130
| +97% | +$273K | ﹤0.01% | 1823 |
|
|
2016
Q4 | $238K | Sell |
6,300
-5,400
| -46% | -$204K | ﹤0.01% | 2034 |
|
|
2016
Q3 | $442K | Buy |
+11,700
| New | +$258K | ﹤0.01% | 2047 |
|
|
2016
Q1 | – | Sell |
-9,200
| Closed | -$224K | – | 2676 |
|
|
2015
Q4 | $224K | Sell |
9,200
-2,500
| -21% | -$58.3K | ﹤0.01% | 2473 |
|
|
2015
Q3 | $208K | Sell |
11,700
-1,600
| -12% | -$29K | ﹤0.01% | 2476 |
|
|
2015
Q2 | $235K | Buy |
13,300
+5,200
| +64% | +$95.3K | ﹤0.01% | 2511 |
|
|
2015
Q1 | $254K | Buy |
+8,100
| New | +$235K | ﹤0.01% | 2367 |
|
UBS AM's AERI Position: Q4 2022 in Review
UBS AM sold out of Aerie Pharmaceuticals (AERI) in Q4 2022, closing a stake of 53,554 shares — an estimated $810K sold.
UBS AM first reported a position in AERI in Q1 2015 and held it in 29 quarters. The position peaked at $6.86M in Q4 2017. 0 funds tracked by Wall St. Rank hold AERI as of Q4 2022.
- UBS AM reported no remaining Aerie Pharmaceuticals position as of Q4 2022 after selling out during the quarter.
- UBS AM sold 53,554 Aerie Pharmaceuticals shares in Q4 2022, an estimated $810K.
- UBS AM first reported a position in Aerie Pharmaceuticals in Q1 2015 and held it in 29 quarters.
- UBS AM's Aerie Pharmaceuticals position peaked at $6.86M in Q4 2017.
- 0 funds tracked by Wall St. Rank held Aerie Pharmaceuticals as of Q4 2022.
Based on UBS AM's 13F filing for Q4 2022, filed 14 Feb 2023.